-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 23, Ascent Pharmaceuticals (6855.
Melanoma is a potentially fatal malignant tumor, and its incidence continues to rise throughout the world
The FTD award is based on the results of APG-115's preclinical research and preliminary clinical data from an ongoing phase II clinical trial (APG-115-US-002, NCT03611868)
FTD aims to accelerate the development and rapid review of drugs for serious diseases in order to solve the serious unmet clinical medical needs in key areas
Dr.
About APG-115
About APG-115APG-115 is an oral, highly selective, small-molecule MDM2 inhibitor independently developed by Yasheng Pharmaceutical.
About Yasheng Pharmaceutical
About Yasheng PharmaceuticalAscent Pharmaceuticals is an original innovative drug research and development company based in China and facing the world in the clinical development stage.
Ascent Pharmaceuticals has a self-constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug development in the apoptosis pathway in the world
Relying on strong R&D capabilities, Yasheng Pharmaceuticals has deployed intellectual property rights worldwide, and has cooperated with leading biotechnology and pharmaceutical companies such as UNITY, MD Anderson, Mayo Medical Center, Dana-Farber Cancer Institute, Merck, AstraZeneca, etc.
references:
1.
2.
4.